Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Breast Cancer

  Free Subscription

Articles published in Eur J Cancer

Retrieve available abstracts of 114 articles:
HTML format

Single Articles

    July 2022
  1. ANDERSON RA, Lambertini M, Hall PS, Wallace WH, et al
    Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy.
    Eur J Cancer. 2022;173:113-122.
    PubMed     Abstract available

  2. LEONE JP, Graham N, Tolaney SM, Leone BA, et al
    Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool.
    Eur J Cancer. 2022;173:20-29.
    PubMed     Abstract available

  3. ALMSTEDT K, Heimes AS, Kappenberg F, Battista MJ, et al
    Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer.
    Eur J Cancer. 2022;173:10-19.
    PubMed     Abstract available

  4. DING L, Poelhekken K, Greuter MJW, Truyen I, et al
    Overdiagnosis of invasive breast cancer in population-based breast cancer screening: A short- and long-term perspective.
    Eur J Cancer. 2022;173:1-9.
    PubMed     Abstract available

  5. BUDDE A, Baust K, Weinhold L, Bernstein M, et al
    Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma.
    Eur J Cancer. 2022;170:209-235.
    PubMed     Abstract available

    June 2022
  6. BATTISTI NML, De Glas N, Soto-Perez-de-Celis E, Liposits G, et al
    Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review.
    Eur J Cancer. 2022;172:158-170.
    PubMed     Abstract available

  7. ESTEVES F, Xavier JM, Ford AM, Rocha C, et al
    Germline allelic expression of genes at 17q22 locus associates with risk of breast cancer.
    Eur J Cancer. 2022;172:146-157.
    PubMed     Abstract available

    Preventing late recurrence in hormone receptor-positive early breast cancer: a review.
    Eur J Cancer. 2022;172:53-64.
    PubMed     Abstract available

  9. YAMADA A, Hayashi N, Kumamaru H, Nagahashi M, et al
    Prognostic impact of postoperative radiotherapy in patients with breast cancer and with pT1-2 and 1-3 lymph node metastases: A retrospective cohort study based on the Japanese Breast Cancer Registry.
    Eur J Cancer. 2022;172:31-40.
    PubMed     Abstract available

  10. OZAKI Y, Tsurutani J, Mukohara T, Iwasa T, et al
    Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B).
    Eur J Cancer. 2022;171:193-202.
    PubMed     Abstract available

  11. MULLER V, Hein A, Hartkopf AD, Fasching PA, et al
    Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
    Eur J Cancer. 2022;172:13-21.
    PubMed     Abstract available

  12. ZHANG J, Gao HF, Yang C, Zhu T, et al
    Prevention of taxane-associated acute pain syndrome with etoricoxib for patients with breast cancer: A phase II randomised trial.
    Eur J Cancer. 2022;171:150-160.
    PubMed     Abstract available

  13. VAN BERGE HENEGOUWEN JM, Jebbink M, Hoes LR, van der Wijngaart H, et al
    Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.
    Eur J Cancer. 2022;171:114-123.
    PubMed     Abstract available

    Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study: Higher visceral tumour burden and weak estrogen rece
    Eur J Cancer. 2022;171:43.

  15. HEIMOVAARA JH, Boere IA, de Haan J, van Calsteren K, et al
    Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands.
    Eur J Cancer. 2022;171:13-21.
    PubMed     Abstract available

  16. SALGADO R, Fineberg S, De Caluwe A, de Azambuja E, et al
    Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively.
    Eur J Cancer. 2022;168:138-140.

  17. SCHIZA A, Thurfjell V, Stenmark Tullberg A, Olofsson H, et al
    Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial.
    Eur J Cancer. 2022;168:128-137.
    PubMed     Abstract available

    May 2022
  18. AMANT F, Nekljudova V, Maggen C, Seither F, et al
    Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.
    Eur J Cancer. 2022;170:54-63.
    PubMed     Abstract available

  19. SHAGISULTANOVA E, Gao D, Callihan E, Parris HJ, et al
    Overall survival is the lowest among young women with postpartum breast cancer.
    Eur J Cancer. 2022;168:119-127.
    PubMed     Abstract available

    April 2022
  20. MASUDA N, Ono M, Mukohara T, Yasojima H, et al
    Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
    Eur J Cancer. 2022;168:108-118.
    PubMed     Abstract available

  21. MARTIN M, Zielinski C, Ruiz-Borrego M, Carrasco E, et al
    Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
    Eur J Cancer. 2022;168:12-24.
    PubMed     Abstract available

  22. GOKER E, Hendriks MP, van Tilburg M, Barcaru A, et al
    Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.
    Eur J Cancer. 2022;167:92-102.
    PubMed     Abstract available

    March 2022
  23. DELALOGE S, Dureau S, D'Hondt V, Desmoulins I, et al
    Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.
    Eur J Cancer. 2022 Mar 22. pii: S0959-8049(22)00035.
    PubMed     Abstract available

  24. GAILLARD T, Carton M, Mailliez A, Desmoulins I, et al
    Corrigendum to "De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis" [Eur J Cancer 158 (2021) 181-188].
    Eur J Cancer. 2022 Mar 18. pii: S0959-8049(22)00119.

  25. GELBER RD, Wang XV, Cole BF, Cameron D, et al
    Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY
    Eur J Cancer. 2022;166:219-228.
    PubMed     Abstract available

  26. VAN MACKELENBERGH MT, Seither F, Mobus V, O'Shaughnessy J, et al
    Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
    Eur J Cancer. 2022;166:185-201.
    PubMed     Abstract available

    February 2022
  27. LIU Z, Wang C, Chen X, Zhu J, et al
    Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
    Eur J Cancer. 2022;165:157-168.
    PubMed     Abstract available

  28. WANG Y, Reulen RC, Kremer LCM, de Vathaire F, et al
    Male breast cancer after childhood cancer: Systematic review and analyses in the PanCareSurFup cohort.
    Eur J Cancer. 2022;165:27-47.
    PubMed     Abstract available

  29. DALENC F, Lusque A, De La Motte Rouge T, Pistilli B, et al
    Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.
    Eur J Cancer. 2022;164:70-79.
    PubMed     Abstract available

  30. PECE S, Sestak I, Montani F, Tillhon M, et al
    Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
    Eur J Cancer. 2022;164:52-61.
    PubMed     Abstract available

  31. MALORNI L, Tyekucheva S, Hilbers FS, Ignatiadis M, et al
    Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
    Eur J Cancer. 2022;164:39-51.
    PubMed     Abstract available

    January 2022
  32. VAN DER PLAS-KRIJGSMAN WG, Morgan JL, de Glas NA, de Boer AZ, et al
    Differences in treatment and survival of older patients with operable breast cancer between the United Kingdom and the Netherlands - A comparison of two national prospective longitudinal multi-centre cohort studies.
    Eur J Cancer. 2022;163:189-199.
    PubMed     Abstract available

  33. KARSTEN MM, Roehle R, Albers S, Pross T, et al
    Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients.
    Eur J Cancer. 2022;163:128-139.
    PubMed     Abstract available

  34. TARANTINO P, Gandini S, Nicolo E, Trillo P, et al
    Evolution of low HER2 expression between early and advanced-stage breast cancer.
    Eur J Cancer. 2022;163:35-43.
    PubMed     Abstract available

  35. UGALDE-MORALES E, Grassmann F, Humphreys K, Li J, et al
    Interval breast cancer is associated with interferon immune response.
    Eur J Cancer. 2022;162:194-205.
    PubMed     Abstract available

    December 2021
  36. IWAMA E, Zenke Y, Sugawara S, Daga H, et al
    Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
    Eur J Cancer. 2021;162:99-106.
    PubMed     Abstract available

  37. PEUKER CA, Yaghobramzi S, Grunert C, Keilholz L, et al
    Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial.
    Eur J Cancer. 2021;162:45-55.
    PubMed     Abstract available

  38. ALBANELL J, Martinez MT, Ramos M, O'Connor M, et al
    Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
    Eur J Cancer. 2021;161:26-37.
    PubMed     Abstract available

  39. JUAN Z, Chen J, Ding B, Yongping L, et al
    Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial.
    Eur J Cancer. 2021;161:10-22.
    PubMed     Abstract available

  40. GOLATTA M, Pfob A, Busch C, Bruckner T, et al
    The potential of combined shear wave and strain elastography to reduce unnecessary biopsies in breast cancer diagnostics - An international, multicentre trial.
    Eur J Cancer. 2021;161:1-9.
    PubMed     Abstract available

    November 2021
  41. PATSOURIS A, Diop K, Tredan O, Nenciu D, et al
    Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.
    Eur J Cancer. 2021;159:283-295.
    PubMed     Abstract available

  42. CORTI C, Giachetti PPMB, Eggermont AMM, Delaloge S, et al
    Therapeutic vaccines for breast cancer: Has the time finally come?
    Eur J Cancer. 2021 Nov 22. pii: S0959-8049(21)01185.
    PubMed     Abstract available

  43. SCHNEEWEISS A, Michel LL, Mobus V, Tesch H, et al
    Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast
    Eur J Cancer. 2021 Nov 17. pii: S0959-8049(21)01164.
    PubMed     Abstract available

  44. HANNOUN-LEVI JM, Gutierrez C, Polgar C, Strnad V, et al
    Letter comments on: The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy.
    Eur J Cancer. 2021;159:224-226.

  45. VICIER C, Sfumato P, Isambert N, Dalenc F, et al
    TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
    Eur J Cancer. 2021;159:205-214.
    PubMed     Abstract available

    October 2021
  46. GAILLARD T, Carton M, Mailliez A, Desmoulins I, et al
    De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis.
    Eur J Cancer. 2021;158:181-188.
    PubMed     Abstract available

  47. CAMPONE M, Bachelot T, Treilleux I, Pistilli B, et al
    A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial).
    Eur J Cancer. 2021;158:169-180.
    PubMed     Abstract available

  48. GARREFFA E, Hamad A, O'Sullivan CC, Hazim AZ, et al
    Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care.
    Eur J Cancer. 2021;159:38-51.
    PubMed     Abstract available

    September 2021
  49. HAN MG, Jang BS, Kang MH, Na D, et al
    PI3Kgammadelta inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Eur J Cancer. 2021;157:450-463.
    PubMed     Abstract available

  50. DAVEY MG, Richard V, Lowery AJ, Kerin MJ, et al
    OncotypeDX(c) Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis.
    Eur J Cancer. 2021;154:209-216.
    PubMed     Abstract available

  51. GUARNERI V, Giorgi CA, Cinieri S, Bengala C, et al
    Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial.
    Eur J Cancer. 2021;154:21-29.
    PubMed     Abstract available

  52. HEIN A, Hartkopf AD, Emons J, Lux MP, et al
    Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status.
    Eur J Cancer. 2021;155:1-12.
    PubMed     Abstract available

    August 2021
  53. CRISCITIELLO C, Marra A, Morganti S, Zagami P, et al
    Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials.
    Eur J Cancer. 2021;157:40-49.
    PubMed     Abstract available

  54. MOBUS V, Luck HJ, Ladda E, Klare P, et al
    Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).
    Eur J Cancer. 2021;156:138-148.
    PubMed     Abstract available

  55. KAHAN Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, et al
    Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
    Eur J Cancer. 2021;156:70-82.
    PubMed     Abstract available

    July 2021
  56. VRIELING C, Assele SY, Moser L, Sauve N, et al
    The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy.
    Eur J Cancer. 2021;155:28-37.
    PubMed     Abstract available

  57. LEFRERE H, Floris G, Schmidt MK, Neven P, et al
    Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome.
    Eur J Cancer. 2021;155:13-24.
    PubMed     Abstract available

  58. HE J, Fu F, Wang W, Xi G, et al
    Prognostic value of tumour-infiltrating lymphocytes based on the evaluation of frequency in patients with oestrogen receptor-positive breast cancer.
    Eur J Cancer. 2021;154:217-226.
    PubMed     Abstract available

  59. YAMADA A, Kumamaru H, Shimizu C, Taira N, et al
    Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry.
    Eur J Cancer. 2021;154:157-166.
    PubMed     Abstract available

  60. LE DU F, Dieras V, Curigliano G
    The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer.
    Eur J Cancer. 2021;154:175-189.
    PubMed     Abstract available

  61. HARTKOPF AD, Brucker SY, Taran FA, Harbeck N, et al
    Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis.
    Eur J Cancer. 2021;154:128-137.
    PubMed     Abstract available

  62. ARUN BK, Han HS, Kaufman B, Wildiers H, et al
    Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.
    Eur J Cancer. 2021;154:35-45.
    PubMed     Abstract available

  63. YUAN Y, Lee JS, Yost SE, Frankel PH, et al
    Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.
    Eur J Cancer. 2021;154:11-20.
    PubMed     Abstract available

    June 2021
  64. MUELLER V, Wardley A, Paplomata E, Hamilton E, et al
    Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
    Eur J Cancer. 2021;153:223-233.
    PubMed     Abstract available

  65. MARME F, Solbach C, Michel L, Schneeweiss A, et al
    Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Eur J Cancer. 2021;153:203-212.
    PubMed     Abstract available

  66. GUARNERI V, Dieci MV, Griguolo G, Miglietta F, et al
    Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.
    Eur J Cancer. 2021;153:133-141.
    PubMed     Abstract available

  67. O'SHAUGHNESSY J, Sousa S, Cruz J, Fallowfield L, et al
    Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
    Eur J Cancer. 2021;152:223-232.
    PubMed     Abstract available

  68. FURLANETTO J, Marme F, Seiler S, Thode C, et al
    Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
    Eur J Cancer. 2021;152:193-203.
    PubMed     Abstract available

  69. BOTTERI E, Baker JG, Sloan EK
    Response to the letter Re: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients.
    Eur J Cancer. 2021 Jun 4. pii: S0959-8049(21)00268.

  70. LYNCH SM, Russell NM, Barron S, Wang CA, et al
    Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
    Eur J Cancer. 2021;152:78-89.
    PubMed     Abstract available

  71. GELMON KA, Fasching PA, Couch FJ, Balmana J, et al
    Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
    Eur J Cancer. 2021;152:68-77.
    PubMed     Abstract available

    May 2021
  72. WOJTYLA C, Bertuccio P, Wojtyla A, La Vecchia C, et al
    European trends in breast cancer mortality, 1980-2017 and predictions to 2025.
    Eur J Cancer. 2021;152:4-17.
    PubMed     Abstract available

  73. DE SANCTIS R, Vigano A, Torrisi R, Santoro A, et al
    Re: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients: Sympathetic nervous system activity on breast cancer: the story of migraine.
    Eur J Cancer. 2021 May 27. pii: S0959-8049(21)00266.

  74. SAESEN R, Lacombe D, Huys I
    Design, organisation and impact of treatment optimisation studies in breast, lung and colorectal cancer: The experience of the European Organisation for Research and Treatment of Cancer.
    Eur J Cancer. 2021;151:221-232.
    PubMed     Abstract available

  75. KIM HJ, Noh WC, Nam SJ, Park BW, et al
    Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report.
    Eur J Cancer. 2021;151:190-200.
    PubMed     Abstract available

  76. LUFTNER D, Tesch H, Schmidt M, Hartkopf AD, et al
    Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study.
    Eur J Cancer. 2021;150:268-277.
    PubMed     Abstract available

  77. ROGADO J, Gullon P, Obispo B, Serrano G, et al
    Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.
    Eur J Cancer. 2021;148:58-60.

  78. MORENO-ASPITIA A, Holmes EM, Jackisch C, de Azambuja E, et al
    Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).
    Eur J Cancer. 2021;148:287-296.
    PubMed     Abstract available

  79. CAMPANALE A, Di Napoli A, Ventimiglia M, Pileri S, et al
    Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients.
    Eur J Cancer. 2021;148:277-286.
    PubMed     Abstract available

  80. VOS H, Lambein K, Wildiers H, Punie K, et al
    Immune-related adverse events after a single dose of pembrolizumab.
    Eur J Cancer. 2021;148:92-94.

    April 2021
  81. ETHIER JL, Anderson GM, Austin PC, Clemons M, et al
    Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R.
    Eur J Cancer. 2021;149:117-127.
    PubMed     Abstract available

    March 2021
  82. PEREZ-GARCIA JM, Llombart-Cussac A, G Cortes M, Curigliano G, et al
    Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase trial.
    Eur J Cancer. 2021;148:382-394.
    PubMed     Abstract available

  83. VILLEGAS SL, Nekljudova V, Pfarr N, Engel J, et al
    Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Eur J Cancer. 2021;148:159-170.
    PubMed     Abstract available

  84. QUINTANA A, Peg V, Prat A, Moline T, et al
    Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer.
    Eur J Cancer. 2021;148:134-145.
    PubMed     Abstract available

  85. MICHAELSON-COHEN R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, et al
    Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
    Eur J Cancer. 2021;148:95-102.
    PubMed     Abstract available

  86. HOUSSAMI N, Zackrisson S, Blazek K, Hunter K, et al
    Meta-analysis of prospective studies evaluating breast cancer detection and interval cancer rates for digital breast tomosynthesis versus mammography population screening.
    Eur J Cancer. 2021;148:14-23.
    PubMed     Abstract available

  87. JEONG JH, Kim JE, Ahn JH, Jung KH, et al
    Corrigendum to "Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study [Eur J Canc 144 (2021) 341-350].
    Eur J Cancer. 2021 Mar 7. pii: S0959-8049(21)00071.

  88. PETRELLI F, Parati MC, Borgonovo K, Cabiddu M, et al
    Adjuvant chemotherapy for pT1abN0M0 triple-negative breast cancer: a systematic review and meta-analysis of published studies.
    Eur J Cancer. 2021;147:151-153.

  89. LI H, Wang J, Yi Z, Li C, et al
    CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
    Eur J Cancer. 2021;145:92-108.
    PubMed     Abstract available

  90. PUJOL P, Barberis M, Beer P, Friedman E, et al
    Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    Eur J Cancer. 2021;146:30-47.
    PubMed     Abstract available

    February 2021
  91. JIANG M, Li CL, Luo XM, Chuan ZR, et al
    Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer.
    Eur J Cancer. 2021;147:95-105.
    PubMed     Abstract available

  92. GILLIS RD, Botteri E, Chang A, Ziegler AI, et al
    Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients.
    Eur J Cancer. 2021;147:106-116.
    PubMed     Abstract available

    January 2021
  93. FURLANETTO J, Mobus V, Schneeweiss A, Rhiem K, et al
    Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
    Eur J Cancer. 2021;145:44-52.
    PubMed     Abstract available

  94. ROBERTSON JFR, Paridaens RJ, Lichfield J, Bradbury I, et al
    Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Eur J Cancer. 2021;145:19-28.
    PubMed     Abstract available

  95. DUBSKY P, Tausch C
    Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by Pfob et al.
    Eur J Cancer. 2021;143:178-179.

  96. PATRIKIDOU A, Cathomas R
    Treading carefully in de-escalation for bone-targeted agents - is less more, after all?
    Eur J Cancer. 2021;142:141-142.

  97. CLEMONS M, Ong M, Stober C, Ernst S, et al
    A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.
    Eur J Cancer. 2021;142:132-140.
    PubMed     Abstract available

    December 2020
  98. R FERREIRA A, Ferreira S, Lambertini M, Maurer C, et al
    Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial.
    Eur J Cancer. 2020;144:351-359.
    PubMed     Abstract available

  99. JEONG JH, Kim JE, Ahn JH, Jung KH, et al
    Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
    Eur J Cancer. 2020;144:341-350.
    PubMed     Abstract available

  100. BATTISTI NML, Reed MWR, Herbert E, Morgan JL, et al
    Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer.
    Eur J Cancer. 2020;144:269-280.
    PubMed     Abstract available

  101. LAKSHMI S, Hughes TA, Priya S
    Exosomes and exosomal RNAs in breast cancer: A status update.
    Eur J Cancer. 2020;144:252-268.
    PubMed     Abstract available

  102. RIBELLES N, Jerez JM, Rodriguez-Brazzarola P, Jimenez B, et al
    Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients.
    Eur J Cancer. 2020;144:224-231.
    PubMed     Abstract available

  103. BOERS J, Venema CM, de Vries EFJ, Hospers GAP, et al
    Serial [(18)F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer.
    Eur J Cancer. 2020;144:151-161.
    PubMed     Abstract available

  104. GERRATANA L, Davis AA, Polano M, Zhang Q, et al
    Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.
    Eur J Cancer. 2020;143:147-157.
    PubMed     Abstract available

  105. PFOB A, Sidey-Gibbons C, Lee HB, Tasoulis MK, et al
    Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy.
    Eur J Cancer. 2020;143:134-146.
    PubMed     Abstract available

  106. KOIVULUOMA S, Tervasmaki A, Kauppila S, Winqvist R, et al
    Exome sequencing identifies a recurrent variant in SERPINA3 associating with hereditary susceptibility to breast cancer.
    Eur J Cancer. 2020;143:46-51.
    PubMed     Abstract available

    November 2020
  107. DAFNI U, Martin-Lluesma S, Balint K, Tsourti Z, et al
    Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
    Eur J Cancer. 2020;142:63-82.
    PubMed     Abstract available

  108. WYLD L, Reed MWR, Morgan J, Collins K, et al
    Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes and quality of life.
    Eur J Cancer. 2020;142:48-62.
    PubMed     Abstract available

  109. COTTU P, Coudert B, Perol D, Doly A, et al
    Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018)
    Eur J Cancer. 2020;141:209-217.
    PubMed     Abstract available

  110. HUBEL K, Kron F, Lux MP
    Biosimilars in oncology: Effects on economy and therapeutic innovations.
    Eur J Cancer. 2020;139:10-19.
    PubMed     Abstract available

    October 2020
  111. STRADELLA A, Del Valle J, Rofes P, Vargas-Parra G, et al
    ERCC3, a new ovarian cancer susceptibility gene?
    Eur J Cancer. 2020;141:1-8.
    PubMed     Abstract available

  112. FINK MK
    Survival in metastatic breast cancer in the ESME study and the ATRESS effect.
    Eur J Cancer. 2020 Oct 3. pii: S0959-8049(20)30495.

  113. DELUCHE E, Antoine A, Bachelot T, Robain M, et al
    A response letter to comments on "Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016".
    Eur J Cancer. 2020 Oct 3. pii: S0959-8049(20)30490.

    September 2020
  114. SALVADOR-COLOMA C, Santaballa A, Sanmartin E, Calvo D, et al
    Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Eur J Cancer. 2020;139:119-134.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.